Department of Economics, Universitat de Barcelona, Barcelona, Spain.
Department of Health Economics, BCN Health Economics & Outcomes Research S.L, Barcelona, Spain.
PLoS One. 2020 Feb 10;15(2):e0228795. doi: 10.1371/journal.pone.0228795. eCollection 2020.
Colorectal cancer incidence in Spain increased considerably between the early nineties and 2010. To reverse this tendency, screenings were progressively implemented starting the year 2001, targeting the population aged 50 to 69 years.
This study aimed to update colorectal cancer incidence and mortality trends in Spain and provide a detailed analysis of disease management and risk factors involved in in-hospital mortality.
To this aim, anonymised primary and specialised care admission records from 2011 to 2016 were extracted from a Spanish claims database representative of all Spanish regions.
Primary care files from 37,317 patients and specialised care files from 192,048 patients were obtained, in which males represented the 56.17% and 60.70% of patients respectively. In-hospital mortality rate was 10.07% and remained stable during the study period, similarly to colorectal cancer incidence within the hospitalised population, which was 106 per 10,000 patients. Patients deceased during the hospitalisation presented an increased presence of metastatic tumours. Mean length of hospital stay decreased significantly over the study period from 13.43 days to 11.67 days (p<0.001), similarly to patients' 30-day readmission rate, which registered a decrease from the 15.29% to 13.58% (p<0.001). In consequence, the direct medical cost measured per patient, of €10,992, decreased over time. The implementation of colorectal cancer screening programmes caused a significant decrease in the number of new diagnoses in patients aged 75 to 79 years that may be attributable to the implementation of colorectal cancer screening programmes; however, in-hospital mortality was not reduced. Metastatic tumours and other conditions as anaemia are associated with higher in-hospital mortality rates.
西班牙的结直肠癌发病率在 90 年代初到 2010 年间大幅上升。为了扭转这一趋势,从 2001 年开始逐步实施筛查,针对 50 至 69 岁的人群。
本研究旨在更新西班牙结直肠癌发病率和死亡率趋势,并详细分析与院内死亡率相关的疾病管理和危险因素。
为此,从代表西班牙所有地区的西班牙索赔数据库中提取了 2011 年至 2016 年的匿名初级和专科护理入院记录。
获得了 37317 名患者的初级护理档案和 192048 名患者的专科护理档案,其中男性分别占患者的 56.17%和 60.70%。院内死亡率为 10.07%,在研究期间保持稳定,与住院人群中的结直肠癌发病率相似,为每 10000 名患者 106 例。住院期间死亡的患者存在更多转移性肿瘤。在研究期间,住院时间的平均值从 13.43 天显著减少至 11.67 天(p<0.001),与患者的 30 天再入院率相似,从 15.29%下降至 13.58%(p<0.001)。因此,每位患者的直接医疗费用从 10992 欧元下降。结直肠癌筛查计划的实施导致 75 至 79 岁患者的新诊断数量显著减少,这可能归因于结直肠癌筛查计划的实施;然而,院内死亡率并未降低。转移性肿瘤和其他疾病(如贫血)与更高的院内死亡率相关。